<p>Cognition Therapeutics, Inc.（納斯達克代碼：CGTX - 獲取免費報告）的股票在覆蓋該股票的五家券商中獲得了 “適度買入” 的共識評級，MarketBeat.com 報道。一位研究分析師給予該股票賣出評級，三位給予買入評級，一位給予強烈買入評級。在過去一年中，發佈報告的分析師對該股票的平均十二個月目標價格為 $3.3333。</p>
<ul>
<li>十一月的小型股寶藏：三隻有望增長的股票</li>
</ul>
<p>CGTX 已成為多份研究報告的主題。B. Riley 在週五的研究報告中重申了 “買入” 評級，並將 Cognition Therapeutics 的目標價格設定為 $3.00（上調自 $2.00）。華爾街 Zen 在 11 月 8 日的研究報告中將 Cognition Therapeutics 的股票評級從 “賣出” 上調至 “持有”。Weiss Ratings 在週二的報告中重申了對 Cognition Therapeutics 股票的 “賣出（d-）” 評級。Chardan Capital 在 8 月 8 日的研究報告中重新發布了 “買入” 評級，並將 Cognition Therapeutics 的目標價格設定為 $4.00。最後，HC Wainwright 在週三的研究報告中重申了 “買入” 評級，並對 Cognition Therapeutics 的股票設定了 $3.00 的目標價格。</p>
<p>獲取 <strong>Cognition Therapeutics</strong> 的提醒：</p>
<p><strong>查看我們最新的 Cognition Therapeutics 股票分析</strong></p>
<h2>Cognition Therapeutics 股票上漲 4.5%</h2>
<p>CGTX 股票在週五上漲 $0.06，達到 $1.39。該公司股票的交易量為 916,768 股，而其平均交易量為 1,075,655 股。Cognition Therapeutics 的十二個月低點為 $0.22，十二個月高點為 $3.83。該股票的 50 日移動平均線為 $1.60，200 日移動平均線為 $1.15。該公司的市值為 $1.227 億，市盈率為 -2.90，貝塔值為 1.23。</p>
<p>Cognition Therapeutics（納斯達克代碼：CGTX - 獲取免費報告）最近於 11 月 6 日發佈了其財報。該公司報告本季度每股收益為 ($0.06)，超出市場共識預期的 ($0.07) $0.01。平均而言，股票研究分析師預測 Cognition Therapeutics 本財年的每股收益為 -0.8。</p>
<h2>Cognition Therapeutics 的機構交易</h2>
<p>一些大型投資者最近對 CGTX 的持倉進行了調整。DAVENPORT &amp; Co LLC 在第三季度購買了 Cognition Therapeutics 的新股份，價值約 $3,631,000。Vanguard Group Inc. 在第三季度將其在 Cognition Therapeutics 的持股增加了 105.6%。Vanguard Group Inc. 現在擁有 2,681,613 股該公司的股票，價值 $3,620,000，此前在此期間又收購了 1,377,263 股。Acadian Asset Management LLC 在第一季度將其在 Cognition Therapeutics 的持股增加了 814.1%。Acadian Asset Management LLC 現在擁有 1,007,586 股該公司的股票，價值 $422,000，此前在上個季度又收購了 897,353 股。Chescapmanager LLC 在第三季度將其在 Cognition Therapeutics 的持股增加了 98.1%。Chescapmanager LLC 現在擁有 997,029 股該公司的股票，價值 $1,346,000，此前在此期間又購買了 493,770 股。最後，Millennium Management LLC 在第三季度收購了 Cognition Therapeutics 的新股份，價值 $757,000。機構投資者和對沖基金持有該公司 43.35% 的股票。</p>
<h2>關於 Cognition Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Cognition Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，專注於發現和開發針對與年齡相關的退行性疾病以及中樞神經系統和視網膜疾病的小分子治療藥物。其主要產品候選藥物是 CT1812，這是一種口服給藥的分子調節劑，旨在穿透血腦屏障並選擇性結合 S2R 複合體，目前正在進行阿爾茨海默病的二期臨牀試驗，以及針對乾性年齡相關性黃斑變性和路易體痴呆等突觸蛋白病的地理萎縮的治療。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Cognition Therapeutics</li>
<li>三隻天然氣股票，提供優厚的股息收益</li>
<li>MP Materials 股票在財報後飆升——真正原因在這裏</li>
<li>為什麼投資高收益股息股票？</li>
<li>為什麼 Palantir 的下滑可能是長期機會的鋪墊</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>收入投資者注意：這隻 REIT 正在打折出售</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Cognition Therapeutics 嗎？</h2>
<p>在考慮投資 Cognition Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Cognition Therapeutics 並不在名單上。</p>
<p>雖然 Cognition Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CGTX

<p>Cognition Therapeutics, Inc.（納斯達克代碼：CGTX）獲得了五家券商的 “適度買入” 共識評級。該股票有一個賣出評級、三個買入評級和一個強力買入評級。平均十二個月目標價為 3.3333 美元。最近的評級包括 B. Riley 的買入評級，目標價為 3.00 美元，以及 Chardan Capital 的買入評級，目標價為 4.00 美元。該股票目前交易價格為 1.39 美元。機構投資者持有該公司 43.35% 的股份</p>

<p>Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been given a consensus rating of &#34;Moderate Buy&#34; by the five brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $3.3333.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc.（納斯達克代碼：CGTX - 獲取免費報告）的股票在覆蓋該股票的五家券商中獲得了 “適度買入” 的共識評級，MarketBeat.com 報道。一位研究分析師給予該股票賣出評級，三位給予買入評級，一位給予強烈買入評級。在過去一年中，發佈報告的分析師對該股票的平均十二個月目標價格為 $3.3333。</p>
</div><ul>
<li>November’s Small-Cap Treasures: 3 Stocks Poised for Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>十一月的小型股寶藏：三隻有望增長的股票</li>
</ul>
</div><p>CGTX has been the subject of a number of research reports. B. Riley reiterated a &#34;buy&#34; rating and set a $3.00 price target (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday. Wall Street Zen raised shares of Cognition Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Cognition Therapeutics in a report on Tuesday. Chardan Capital reissued a &#34;buy&#34; rating and set a $4.00 price objective on shares of Cognition Therapeutics in a research note on Friday, August 8th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research note on Wednesday.</p>
<div class="lb-trans"><p>CGTX 已成為多份研究報告的主題。B. Riley 在週五的研究報告中重申了 “買入” 評級，並將 Cognition Therapeutics 的目標價格設定為 $3.00（上調自 $2.00）。華爾街 Zen 在 11 月 8 日的研究報告中將 Cognition Therapeutics 的股票評級從 “賣出” 上調至 “持有”。Weiss Ratings 在週二的報告中重申了對 Cognition Therapeutics 股票的 “賣出（d-）” 評級。Chardan Capital 在 8 月 8 日的研究報告中重新發布了 “買入” 評級，並將 Cognition Therapeutics 的目標價格設定為 $4.00。最後，HC Wainwright 在週三的研究報告中重申了 “買入” 評級，並對 Cognition Therapeutics 的股票設定了 $3.00 的目標價格。</p>
</div><p>Get <strong>Cognition Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cognition Therapeutics</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Cognition Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Cognition Therapeutics 股票分析</strong></p>
</div><h2>Cognition Therapeutics Stock Up 4.5%</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 股票上漲 4.5%</h2>
</div><p>CGTX stock traded up $0.06 on Friday, reaching $1.39. 916,768 shares of the company's stock were exchanged, compared to its average volume of 1,075,655. Cognition Therapeutics has a twelve month low of $0.22 and a twelve month high of $3.83. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.15. The firm has a market cap of $122.70 million, a PE ratio of -2.90 and a beta of 1.23.</p>
<div class="lb-trans"><p>CGTX 股票在週五上漲 $0.06，達到 $1.39。該公司股票的交易量為 916,768 股，而其平均交易量為 1,075,655 股。Cognition Therapeutics 的十二個月低點為 $0.22，十二個月高點為 $3.83。該股票的 50 日移動平均線為 $1.60，200 日移動平均線為 $1.15。該公司的市值為 $1.227 億，市盈率為 -2.90，貝塔值為 1.23。</p>
</div><p>Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. On average, equities research analysts predict that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cognition Therapeutics（納斯達克代碼：CGTX - 獲取免費報告）最近於 11 月 6 日發佈了其財報。該公司報告本季度每股收益為 ($0.06)，超出市場共識預期的 ($0.07) $0.01。平均而言，股票研究分析師預測 Cognition Therapeutics 本財年的每股收益為 -0.8。</p>
</div><h2>Institutional Trading of Cognition Therapeutics</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 的機構交易</h2>
</div><p>A number of large investors have recently made changes to their positions in CGTX. DAVENPORT &amp; Co LLC purchased a new stake in shares of Cognition Therapeutics during the third quarter worth about $3,631,000. Vanguard Group Inc. grew its stake in Cognition Therapeutics by 105.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company's stock worth $3,620,000 after acquiring an additional 1,377,263 shares during the period. Acadian Asset Management LLC raised its holdings in Cognition Therapeutics by 814.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company's stock valued at $422,000 after acquiring an additional 897,353 shares during the last quarter. Chescapmanager LLC lifted its stake in shares of Cognition Therapeutics by 98.1% during the 3rd quarter. Chescapmanager LLC now owns 997,029 shares of the company's stock worth $1,346,000 after purchasing an additional 493,770 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Cognition Therapeutics during the third quarter worth $757,000. Institutional investors and hedge funds own 43.35% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近對 CGTX 的持倉進行了調整。DAVENPORT &amp; Co LLC 在第三季度購買了 Cognition Therapeutics 的新股份，價值約 $3,631,000。Vanguard Group Inc. 在第三季度將其在 Cognition Therapeutics 的持股增加了 105.6%。Vanguard Group Inc. 現在擁有 2,681,613 股該公司的股票，價值 $3,620,000，此前在此期間又收購了 1,377,263 股。Acadian Asset Management LLC 在第一季度將其在 Cognition Therapeutics 的持股增加了 814.1%。Acadian Asset Management LLC 現在擁有 1,007,586 股該公司的股票，價值 $422,000，此前在上個季度又收購了 897,353 股。Chescapmanager LLC 在第三季度將其在 Cognition Therapeutics 的持股增加了 98.1%。Chescapmanager LLC 現在擁有 997,029 股該公司的股票，價值 $1,346,000，此前在此期間又購買了 493,770 股。最後，Millennium Management LLC 在第三季度收購了 Cognition Therapeutics 的新股份，價值 $757,000。機構投資者和對沖基金持有該公司 43.35% 的股票。</p>
</div><h2>About Cognition Therapeutics</h2>
<div class="lb-trans"><h2>關於 Cognition Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，專注於發現和開發針對與年齡相關的退行性疾病以及中樞神經系統和視網膜疾病的小分子治療藥物。其主要產品候選藥物是 CT1812，這是一種口服給藥的分子調節劑，旨在穿透血腦屏障並選擇性結合 S2R 複合體，目前正在進行阿爾茨海默病的二期臨牀試驗，以及針對乾性年齡相關性黃斑變性和路易體痴呆等突觸蛋白病的地理萎縮的治療。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Cognition Therapeutics</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>MP Materials Stock Soared After Earnings—Here’s the Real Reason</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Why Palantir Slide May Be a Setup for a Long-Term Opportunity</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Attention Income Investors: This REIT Is on Sale</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Cognition Therapeutics</li>
<li>三隻天然氣股票，提供優厚的股息收益</li>
<li>MP Materials 股票在財報後飆升——真正原因在這裏</li>
<li>為什麼投資高收益股息股票？</li>
<li>為什麼 Palantir 的下滑可能是長期機會的鋪墊</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>收入投資者注意：這隻 REIT 正在打折出售</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CGTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cognition Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Cognition Therapeutics 嗎？</h2>
</div><p>Before you consider Cognition Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Cognition Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Cognition Therapeutics 並不在名單上。</p>
</div><p>While Cognition Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cognition Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cognition Therapeutics, Inc.（納斯達克股票代碼：CGTX）被分析師一致推薦為 “適度買入”